Results 1 to 10 of about 372,959 (96)
Effect of etanercept on post-traumatic proliferative vitreoretinopathy [PDF]
International Journal of Ophthalmology, 2019 AIM: To evaluate the safety and efficacy of intravitreal etanercept in the inhibiting of proliferative vitreoretinopathy (PVR) in a model of penetrating ocular injury.
Xiao-Feng Chen +3 more
doaj +2 more sources
Salinomycin inhibits proliferative vitreoretinopathy formation in a mouse model.
PLoS ONE, 2020 Proliferative vitreoretinopathy (PVR) is a progressive disease that develops in a subset of patients who undergo surgery for retinal detachment repair, and results in significant vision loss.
Alison M Heffer +5 more
doaj +2 more sources
A sustained dual drug delivery system for proliferative vitreoretinopathy
Drug Delivery, 2020 Proliferative vitreoretinopathy (PVR) is a significant threat for vision recovery from retinal detachment or ocular trauma. Currently, no approved pharmacological intervention to prevent PVR.
Ying Xiao +7 more
doaj +2 more sources
Risk factors for failure after primary vitrectomy with no scleral buckling for rhegmatogenous retinal detachment [PDF]
Revista Brasileira de Oftalmologia, 2023 Objective To assess pre-operative conditions that could influence primary anatomical success rate in a cohort of patients with rhegmatogenous retinal detachments (RRD) treated with primary vitrectomy and no scleral buckling.
Mariano Iros +4 more
doaj +1 more source
Experimental Models to Study Epithelial-Mesenchymal Transition in Proliferative Vitreoretinopathy
International Journal of Molecular Sciences, 2023 Proliferative vitreoretinal diseases (PVDs) encompass proliferative vitreoretinopathy (PVR), epiretinal membranes, and proliferative diabetic retinopathy.
Azine Datlibagi +5 more
semanticscholar +1 more source
Офтальмохирургия, 2023 Relevance. Currently, there is no single algorithm for the management of patients with extensive penetrating wounds of the sclera, and the frequency of proliferative vitreoretinopathy, leading to adverse outcomes, is very high. Purpose.
S.S. Shamkin, S.N. Subbotina
doaj +1 more source
Proliferative Vitreoretinopathy: A Reappraisal
Journal of Clinical Medicine, 2023 Proliferative vitreoretinopathy (PVR) remains the main cause of failure after retinal detachment (RD) surgery. Despite the development of modern technologies and sophisticated techniques for the management of RD, the growth of fibrocellular membranes ...
P. Carpineto +2 more
semanticscholar +1 more source
Case Reports in Ophthalmology, 2022 Our case emphasizes the approach of a single-dose of intraoperative methotrexate (MTX) – applied directly into silicone oil – to arrest the anomalous progression of proliferative vitreoretinopathy (PVR).
Adrian Babel +2 more
doaj +1 more source
Proliferative vitreoretinopathy: an update on the current and emerging treatment options
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2023 Proliferative vitreoretinopathy (PVR) remains the main cause of failure in retinal detachment (RD) surgery and a demanding challenge for vitreoretinal surgeons.
L. Ferro Desideri +4 more
semanticscholar +1 more source
Low-Dose Intravitreal Methotrexate for Proliferative Vitreoretinopathy.
Ophthalmic Surgery Lasers and Imaging Retina, 2023 BACKGROUND AND OBJECTIVE Proliferative vitreoretinopathy (PVR) has been mitigated by intravitreal methotrexate (MTX) 400 μg/0.1 mL in several studies. Here, we evaluate the results from a lower dose of MTX, 200 μg/0.05 mL.
Asm S Ullah +5 more
semanticscholar +1 more source